Lupin partners with SUP to bring Tiotropium DPI to China, enhancing respiratory care access through regulatory and manufacturing collaboration.

• Lupin markets and manufactures Tiotropium DPI, ensuring timely access to innovative respiratory treatments in China.
• SUP secures regulatory approvals, leveraging expertise to fast-track Tiotropium DPI's availability for COPD patients.
• Tiotropium DPI improves lung function and quality of life, addressing rising respiratory disease prevalence in China.